Welcome to our dedicated page for Codexis news (Ticker: CDXS), a resource for investors and traders seeking the latest updates and insights on Codexis stock.
Codexis, Inc. (NASDAQ: CDXS) generates news primarily around its enzymatic technologies for therapeutics manufacturing and the development of its ECO Synthesis® / ECO Synthesis™ manufacturing platform. The company’s announcements frequently highlight progress in applying enzyme-based processes to small molecule pharmaceuticals manufacturing and nucleic acid synthesis, as well as steps toward enabling scaled manufacture of RNAi therapeutics, including siRNA and other oligonucleotides, through enzymatic routes.
News about Codexis often covers financial results and business updates, where the company reports on revenues, product gross margins, research and development spending, and strategic priorities. These releases typically include commentary on the performance of its Pharma Biocatalysis business, the status of ECO Synthesis-related activities, and the company’s cash position and funding plans as disclosed in its quarterly and annual reporting cycles.
Another recurring theme in Codexis news is collaborations and evaluation agreements with organizations involved in oligonucleotide therapeutics. The company has announced agreements with CDMOs and CRDMOs such as Nitto Denko Avecia and Axolabs to evaluate the ECO Synthesis manufacturing platform for therapeutic siRNA and other oligonucleotides. These updates describe how partners assess Codexis’s enzymatic approach and indicate that such evaluations may lead to licensing discussions and broader adoption.
Codexis also issues news about infrastructure and strategic initiatives, including the signing of a lease for a GMP manufacturing facility in Hayward, California, intended to support GMP manufacturing of siRNA and other oligonucleotides using ECO Synthesis. Additional releases detail organizational changes, leadership transitions, workforce streamlining aligned with an enhanced focus on ECO Synthesis, and participation in industry conferences such as TIDES USA and TIDES Europe, where Codexis and its collaborators present data on enzymatic manufacturing technologies.
Investors and observers who follow CDXS news can use this stream of updates to monitor Codexis’s progress in advancing enzyme-based manufacturing platforms, its relationships with manufacturing partners, and its evolving strategic focus within therapeutics manufacturing.
Codexis (Nasdaq:CDXS) announced plans to expand operations with a new 36,000 square foot facility in San Carlos, CA, under a ten-year lease. This strategic move aims to enhance research and development capabilities, accommodating around 90 employees. The facility is expected to be ready by Q4 2021. CEO John Nicols highlighted the company's rapid growth in life sciences and sustainable manufacturing, anticipating continued acceleration through new partnerships and self-funded clinical programs.
Codexis (Nasdaq:CDXS) announced the appointment of Esther Martinborough, Ph.D., to its board of directors, expanding the board to ten members. Dr. Martinborough brings over two decades of experience in drug discovery and development, having played a key role in the successful approval of Zeposia® for Multiple Sclerosis. Currently the Senior Vice President of Research at Escient Pharmaceuticals, her expertise is expected to contribute significantly to Codexis’ Biotherapeutics initiatives, enhancing its product development capabilities.
Codexis (CDXS) has extended its collaboration with Tate & Lyle, focusing on advancing the production of the DOLCIA PRIMA® Allulose and TASTEVA® M Stevia Sweetener. This partnership aims to improve production efficiencies through novel enzyme products developed by Codexis, potentially reducing costs linked to these sweeteners. Tate & Lyle’s new offerings target healthier consumer options, addressing diabetes and obesity issues. The collaboration, ongoing for seven years, underscores the importance of Codexis's enzyme technology in supporting Tate & Lyle's product development.
Codexis (Nasdaq:CDXS) announces that President and CEO John Nicols will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference from January 11-14, 2021. The recorded session will be accessible starting January 11 at 6:00 a.m. ET on the company's investor website, available for 30 days. Codexis specializes in protein engineering, utilizing its CodeEvolver® technology to enhance protein performance for pharmaceuticals, enzymes, and diagnostics, promoting sustainable manufacturing processes.
Codexis (Nasdaq: CDXS) announced a public offering of 4,285,715 shares at $17.50 each, aiming to raise approximately $70.2 million after expenses. The offering is expected to close around December 7, 2020, pending customary conditions. Proceeds will support R&D and infrastructure to enhance performance enzymes and biotherapeutics, as well as fund potential acquisitions or investments. Jefferies LLC, Cowen and Company, LLC, and Stifel are managing the offering, with an additional 642,857 shares available for underwriters within 30 days.
Codexis (Nasdaq: CDXS) has launched an underwritten public offering of its common stock, with plans to grant underwriters a 30-day option to purchase an additional 15% of shares. The net proceeds will fund R&D, enhance infrastructure, and support the development of performance enzymes and biotherapeutics. Codexis may also invest in complementary businesses. Notably, Jefferies LLC, Cowen and Company, and Stifel are managing the offering. Market conditions may impact the completion and terms of this offering.
Codexis (NASDAQ: CDXS) and Casdin Capital have launched the SynBio Innovation Accelerator, aimed at funding early-stage companies in synthetic biology. This initiative will see Casdin planning to invest upwards of $50 million in the sector. The first investment is a $1.75 million stake in Arzeda, a computational protein design firm, where both companies will collaborate to enhance enzyme development using machine learning. John Nicols, CEO of Codexis, emphasized the transformative potential of synthetic biology, while Eli Casdin highlighted the accelerator's role in stimulating innovation.
Codexis, a leader in protein engineering, announced its participation in three virtual investment conferences. The events include the Stifel Healthcare Conference on November 16, 2020, at 3:20 p.m. ET, the 11th Annual Craig-Hallum Alpha Select Conference on November 17, 2020, and the Stephens Annual Investment Conference on November 18, 2020, at 1:00 p.m. ET. Presentations will be webcasted and available for replay on the company's investor website. Codexis utilizes its proprietary technology for developing proteins for pharmaceuticals and industrial applications.
Codexis, Inc. (Nasdaq: CDXS) reported total revenues of $18.4 million for Q3 2020, a drop from $21.9 million in Q3 2019. Product revenue was $8.4 million, down from $10.4 million year-over-year, largely due to demand timing. R&D revenue decreased to $10.0 million from $11.6 million, impacted by fewer milestone payments. Despite a net loss of $6.1 million, management expects 2020 revenue to exceed pre-COVID guidance, with robust growth across its segments, including Novel Biotherapeutics.
Codexis, a leader in protein engineering, is set to announce its third quarter 2020 financial results on November 5, 2020, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide company updates. Investors are encouraged to pre-register for the call to streamline access. The announcement underlines Codexis' focus on transparency and engagement with its investment community.
FAQ
What is the current stock price of Codexis (CDXS)?
What is the market cap of Codexis (CDXS)?
